can be found in the epithelial cells of the distal epididymis and the vas deferens and is acquired by sperm cells during their passage through the genital tract 3 . The structure of the CD52 protein is unusual. It is a very small, heavily glycosylated antigen with glycolipid-like properties. The sperm CD52 protein differs from the lymphocyte CD52 protein in its carbohydrate structure 4 . The physiological role of CD52 on lymphocytes is unclear. The high density of CD52 and the close proximity of the antibody binding site to the cell surface make it a particularly good target for therapeutic options 5 . These properties may contribute to the efficacy of the therapeutically used CD52 antibody, also called CAMPATH-1H (Alemtuzumab). CAMPATH-1H is capable of complementactivation and antibody-mediated cellular cytotoxicity leading to a depletion of lymphocytes 6, 7 . Stanglmaier et al. also suggested a caspase-independent form of apoptosis that may be induced by CAMPATH-1H in patients with chronic lymphocytic leukaemia 8 . At present, CD52-specific antibodies are used to treat lympho-proliferative disorders like B-cell chronic lymphocytic leukaemia, to deplete lymphocytes in bone marrow transplants, in the therapy of transplant rejection, to control graft versus host disease and, most recently, to treat Behcet's disease and multiple sclerosis [9] [10] [11] [12] [13] [14] .
By microarray analysis, we found that CD52 mRNA is significantly overexpressed in giant cell tumours of the bone 15 . Further experiments revealed a significant upregulation of CD52 mRNA in chondrosarcoma and osteosarcoma tissue samples, suggesting a previously unknown deregulation of CD52 in bone malignancies. Therefore, CAMPATH-1H might have therapeutic potential for osteosarcoma patients with poor clinical prognosis. secondary antibody. Blots were developed using the ECL system from Amersham.
Material and Methods

Tissue studies
Patients and tissues
Results
Tissue studies
Increased CD52 expression in bone malignancies
RNA derived from eight osteosarcoma samples (n=4 conventional, n=4 metastases) and from the human osteoblast primary culture HOBc was analysed using Affymetrix HG U133A microarrays (GEO accession number GSE14359; Guenther et al. submitted). A significantly higher expression of CD52 was found in osteosarcoma metastases as compared to conventional osteosarcoma (p=0.000619). CD52 mRNA levels were below background in HOBc cells and the conventional osteosarcomas, except for in the OS18 cell line (relative expression level of 1,022 and 1,336). In the microarray analysis of primary and recurrent giant cell tumours of bone, CD52 mRNA was lower in recurrent as compared to primary giant cell tumours 15 .
For the validation of microarray data, 14 osteosarcoma tissue samples (n=7 conventional and n=7 lung metastases) and 26 giant cell tumour tissue samples (n=18 primary, n=8 recurrence) were stained for CD52. As a control, a tissue microarray of non-neoplastic bone samples containing 4 foetal and 6 adult samples was used. High levels of CD52 protein were seen in foetal bone (Fig. 1A) , while adult bone had lower CD52 levels (Fig. 1B) . Interestingly, the osteoblasts in foetal bone samples showed the strongest CD52 staining, while the osteoblasts in adult bone were CD52 negative or showed only weak expression of CD52. We also found a largely cytoplasmic localisation, with only rare cases having a nuclear expression pattern of CD52 protein.
The osteocytes were CD52 positive in foetal and adult bone (Fig. 1A, B) . The primary (Fig. 1C) . All ostoesarcoma samples showed a strong immunoreactivity for the CD52 antigen (IRS 6.1), but no significant differences could be observed between the conventional osteosarcomas and the metastases (p=0.515). The latter showed generally a lower CD52 expression (IRS=5.6) as compared to the conventional osteosarcomas (IRS=6.6). In most cases, the CD52 staining was cytoplasmic, but some nuclear localisation could also be observed (Fig. 1D ).
CD52 protein was detected in 18/18 primary giant cell tumours and 8/8
recurrence samples. The macrophage-like cells and the multinucleated giant cells showed on average a moderate cytoplasmic staining intensity (Fig. 1E ).
High expression of CD52 in chondrosarcoma and cartilage
CD52 protein expression was also tested in non-neoplastic and neoplastic cartilage samples. The non-neoplastic tissue microarray included 4 embryonal, 6 foetal and 10 adult cartilage tissue samples, and the neoplastic tissue array had 6 chondrosarcoma tissue samples. Non-neoplastic cartilage was CD52 negative in all embryonal ( Fig. 2A) and in 4/5 foetal cartilage samples (Fig. 2B) . Only one foetal cartilage tissue had low CD52 expression. In contrast, CD52 expression could be observed in chondrocytes of adult cartilage by immunohistochemistry (Fig. 2C) . Furthermore, a primary chondrocyte culture showed a low cytoplasmic CD52 expression (Fig. 2D) . showed a moderate cytoplasmic expression of CD52, whereas in the grade 3 samples a strong cytoplasmic CD52 staining could be observed (Fig. 2E) . Because of the small 
CD52 expression is rare in skeletal tumours
In addition to osteosarcoma, chondrosarcoma and giant cell tumours, benign bone-and cartilage-related, malignant fibrous and skeletal tumours with undefined origin (fibrous dysplasia and aneurysmal bone cyst) were analysed for CD52 expression. Results from immunohistochemical evaluation of all skeletal tumours are shown in Table 2 .
Cytoplasmic and nuclear CD52 expression could be detected in 4/5 benign chondromas (Fig. 3A) , 2/3 benign osteochondromas (Fig. 3B ), 3/3 malignant fibrosarcomas ( Fig.   3C ), 3/3 benign aneurysmal bone cysts (Fig. 3D ) and 5/5 benign osteomas (Fig. 3E ).
Fibrous dysplasia stained weakly and CD52 protein was only detected in the stroma (Fig. 3F) .
In vitro studies
Membranous and intracellular localisation of CD52
Immunohistochemical staining suggested a dual localisation of CD52 both on the surface of the cells, as expected for GPI-anchored glycoproteins, but also in the cytoplasm. To analyse the intra-and extracellular expression of CD52, flow cytometric analysis was performed using the CD52 FITC-conjugated antibody in osteosarcoma and chondrosarcoma cell lines, giant cell tumour and chondrocyte and osteoblast primary cultures (Table 3 , Fig. 4 ). The human T-cell lymphoma cell line Hut78 was included as a positive control due to known expression of CD52 17 .
Staining of Hut78 for membranous and intracellular CD52 revealed 32% and 93% positive cells, respectively (Fig. 4A) . In MNNG/HOS osteosarcoma cells, 10% of cells showed a membranous staining, while 69% showed an intracellular staining ( (Fig. 4E) . The highest membranous expression could be detected in the giant cell tumour primary culture, with 20% positive stained cells (Fig. 4F) .
CAMPATH-1H inhibits growth of osteosarcoma cells
The therapeutic CD52 antibody CAMPATH-1H was shown to deplete lymphocytes through antibody-dependent cytotoxicity or complement-dependent cytotoxicity. To study the effect of the CAMPATH-1H antibody on bone tumours, we incubated the human osteosarcoma cell line MNNG/HOS with 50 µg/ml or 100 µg/ml CAMPATH-1H and assayed for cell growth.
Using 50 µg/ml and 100 µg/ml CAMPATH-1H in media containing 10% human complement, a significant reduction of proliferating MNNG/HOS cells was observed when compared to cells incubated with inactive complement (50 µg/ml p=0.026, 100 µg/ml p=0.021; Fig. 5A ). To test the specificity of CAMPATH-1H, the same assay was performed in the absence of human complement. This assay demonstrated a dose-( treated cells, no cleaved PARP product was observed, suggesting an apoptosisindependent mechanism of cell growth inhibition (Fig. 5D ). Interestingly, an intracellular expression of CD52 flow cytometry could be detected. In a previous study, the GPI-anchored protein EFNA1 was also shown to be expressed intracellularly, which could be due to abnormalities in GPI-anchor biosynthesis or failure of GPI transport resulting in an intracellular localisation of 
